• Je něco špatně v tomto záznamu ?

Enzymatic sialylation of IgA1 O-glycans: implications for studies of IgA nephropathy

K. Takahashi, M. Raska, M. Stuchlova Horynova, SD. Hall, K. Poulsen, M. Kilian, Y. Hiki, Y. Yuzawa, Z. Moldoveanu, BA. Julian, MB. Renfrow, J. Novak,

. 2014 ; 9 (2) : e99026. [pub] 20140611

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, Research Support, N.I.H., Extramural, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc16000736

Patients with IgA nephropathy (IgAN) have elevated circulating levels of IgA1 with some O-glycans consisting of galactose (Gal)-deficient N-acetylgalactosamine (GalNAc) with or without N-acetylneuraminic acid (NeuAc). We have analyzed O-glycosylation heterogeneity of naturally asialo-IgA1 (Ale) myeloma protein that mimics Gal-deficient IgA1 (Gd-IgA1) of patients with IgAN, except that IgA1 O-glycans of IgAN patients are frequently sialylated. Specifically, serum IgA1 of healthy controls has more α2,3-sialylated O-glycans (NeuAc attached to Gal) than α2,6-sialylated O-glycans (NeuAc attached to GalNAc). As IgA1-producing cells from IgAN patients have an increased activity of α2,6-sialyltransferase (ST6GalNAc), we hypothesize that such activity may promote premature sialylation of GalNAc and, thus, production of Gd-IgA1, as sialylation of GalNAc prevents subsequent Gal attachment. Distribution of NeuAc in IgA1 O-glycans may play an important role in the pathogenesis of IgAN. To better understand biological functions of NeuAc in IgA1, we established protocols for enzymatic sialylation leading to α2,3- or α2,6-sialylation of IgA1 O-glycans. Sialylation of Gal-deficient asialo-IgA1 (Ale) myeloma protein by an ST6GalNAc enzyme generated sialylated IgA1 that mimics the Gal-deficient IgA1 glycoforms in patients with IgAN, characterized by α2,6-sialylated Gal-deficient GalNAc. In contrast, sialylation of the same myeloma protein by an α2,3-sialyltransferase yielded IgA1 typical for healthy controls, characterized by α2,3-sialylated Gal. The GalNAc-specific lectin from Helix aspersa (HAA) is used to measure levels of Gd-IgA1. We assessed HAA binding to IgA1 sialylated at Gal or GalNAc. As expected, α2,6-sialylation of IgA1 markedly decreased reactivity with HAA. Notably, α2,3-sialylation also decreased reactivity with HAA. Neuraminidase treatment recovered the original HAA reactivity in both instances. These results suggest that binding of a GalNAc-specific lectin is modulated by sialylation of GalNAc as well as Gal in the clustered IgA1 O-glycans. Thus, enzymatic sialylation offers a useful model to test the role of NeuAc in reactivities of the clustered O-glycans with lectins.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16000736
003      
CZ-PrNML
005      
20160108120828.0
007      
ta
008      
160108s2014 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pone.0099026 $2 doi
035    __
$a (PubMed)24918438
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Takahashi, Kazuo $u Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America; Department of Nephrology, Fujita Health University School of Medicine, Toyoake, Japan.
245    10
$a Enzymatic sialylation of IgA1 O-glycans: implications for studies of IgA nephropathy / $c K. Takahashi, M. Raska, M. Stuchlova Horynova, SD. Hall, K. Poulsen, M. Kilian, Y. Hiki, Y. Yuzawa, Z. Moldoveanu, BA. Julian, MB. Renfrow, J. Novak,
520    9_
$a Patients with IgA nephropathy (IgAN) have elevated circulating levels of IgA1 with some O-glycans consisting of galactose (Gal)-deficient N-acetylgalactosamine (GalNAc) with or without N-acetylneuraminic acid (NeuAc). We have analyzed O-glycosylation heterogeneity of naturally asialo-IgA1 (Ale) myeloma protein that mimics Gal-deficient IgA1 (Gd-IgA1) of patients with IgAN, except that IgA1 O-glycans of IgAN patients are frequently sialylated. Specifically, serum IgA1 of healthy controls has more α2,3-sialylated O-glycans (NeuAc attached to Gal) than α2,6-sialylated O-glycans (NeuAc attached to GalNAc). As IgA1-producing cells from IgAN patients have an increased activity of α2,6-sialyltransferase (ST6GalNAc), we hypothesize that such activity may promote premature sialylation of GalNAc and, thus, production of Gd-IgA1, as sialylation of GalNAc prevents subsequent Gal attachment. Distribution of NeuAc in IgA1 O-glycans may play an important role in the pathogenesis of IgAN. To better understand biological functions of NeuAc in IgA1, we established protocols for enzymatic sialylation leading to α2,3- or α2,6-sialylation of IgA1 O-glycans. Sialylation of Gal-deficient asialo-IgA1 (Ale) myeloma protein by an ST6GalNAc enzyme generated sialylated IgA1 that mimics the Gal-deficient IgA1 glycoforms in patients with IgAN, characterized by α2,6-sialylated Gal-deficient GalNAc. In contrast, sialylation of the same myeloma protein by an α2,3-sialyltransferase yielded IgA1 typical for healthy controls, characterized by α2,3-sialylated Gal. The GalNAc-specific lectin from Helix aspersa (HAA) is used to measure levels of Gd-IgA1. We assessed HAA binding to IgA1 sialylated at Gal or GalNAc. As expected, α2,6-sialylation of IgA1 markedly decreased reactivity with HAA. Notably, α2,3-sialylation also decreased reactivity with HAA. Neuraminidase treatment recovered the original HAA reactivity in both instances. These results suggest that binding of a GalNAc-specific lectin is modulated by sialylation of GalNAc as well as Gal in the clustered IgA1 O-glycans. Thus, enzymatic sialylation offers a useful model to test the role of NeuAc in reactivities of the clustered O-glycans with lectins.
650    _2
$a sekvence aminokyselin $7 D000595
650    _2
$a zvířata $7 D000818
650    _2
$a sacharidové sekvence $7 D002240
650    _2
$a IgA nefropatie $x metabolismus $7 D005922
650    _2
$a glykosyltransferasy $x metabolismus $7 D016695
650    _2
$a HEK293 buňky $7 D057809
650    _2
$a Helix (hlemýždi) $x metabolismus $7 D006372
650    _2
$a lidé $7 D006801
650    _2
$a imunoglobulin A $x chemie $x metabolismus $7 D007070
650    _2
$a lektiny $x metabolismus $7 D037102
650    _2
$a molekulární sekvence - údaje $7 D008969
650    _2
$a polysacharidy $x chemie $x metabolismus $7 D011134
650    _2
$a rekombinantní proteiny $x metabolismus $7 D011994
650    _2
$a kyseliny sialové $x analýza $x metabolismus $7 D012794
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Raska, Milan $u Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America; Faculty of Medicine and Dentistry, Department of Immunology, Palacky University in Olomouc, Olomouc, Czech Republic.
700    1_
$a Stuchlova Horynova, Milada $u Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America; Faculty of Medicine and Dentistry, Department of Immunology, Palacky University in Olomouc, Olomouc, Czech Republic.
700    1_
$a Hall, Stacy D $u Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.
700    1_
$a Poulsen, Knud $u Department of Biomedicine, Aarhus University, Aarhus, Denmark.
700    1_
$a Kilian, Mogens $u Department of Biomedicine, Aarhus University, Aarhus, Denmark.
700    1_
$a Hiki, Yoshiyuki $u Fujita Health University School of Health Sciences, Toyoake, Japan.
700    1_
$a Yuzawa, Yukio $u Department of Nephrology, Fujita Health University School of Medicine, Toyoake, Japan.
700    1_
$a Moldoveanu, Zina $u Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.
700    1_
$a Julian, Bruce A $u Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America; Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.
700    1_
$a Renfrow, Matthew B $u UAB Biomedical FT-ICR MS Laboratory, Department of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.
700    1_
$a Novak, Jan $u Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.
773    0_
$w MED00180950 $t PloS one $x 1932-6203 $g Roč. 9, č. 2 (2014), s. e99026
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24918438 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160108 $b ABA008
991    __
$a 20160108120938 $b ABA008
999    __
$a ok $b bmc $g 1103017 $s 924942
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 9 $c 2 $d e99026 $e 20140611 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
LZP    __
$a Pubmed-20160108

Najít záznam

Citační ukazatele

    Možnosti archivace